Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Merck acquires oncology spinout Modifi Biosciences in deal worth $1.3bn

The agreement gives Merck access to a new class of small molecules for difficult-to-treat cancers

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer

Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth

- PMLiVE

Medicines can be beyond reach – unless…

Solving the access to medicines problem needs an evolutionary leap

- PMLiVE

Innovative Trials named a top UK women-powered company in clinical research by J.P. Morgan

Innovative Trials has been named the second-fastest-growing, women-powered UK company in clinical research and ranks among the top 200 women-powered businesses in the UK!

Innovative Trials

Pharma apps

Beyond the Pill: The Power of Pharma Companion Apps

Pharma companion apps are transforming healthcare by offering support beyond traditional treatments, enhancing patient engagement and outcomes. From medication reminders to symptom tracking, these apps provide valuable tools for both...

Genetic Digital

3 New trends in CME

3 New trends in CME

The landscape of continuing medical education (CME) is undergoing significant transformations. Driven by the latest advancements and innovations, digital learning programs have made CME even more accessible and personalized. Learn...

Wiley

- PMLiVE

J&J’s Darzalex regimen approved by EC for newly diagnosed multiple myeloma

More than 35,000 cases of the incurable blood cancer were diagnosed in the EU in 2022

- PMLiVE

Novartis’ Kisqali receives CHMP recommendation for early breast cancer patients

Approximately 70% of all breast cancer patients have HR-positive/HER2-negative disease

- PMLiVE

The role of innovation in shaping the future of health communications

The future is full of potential – if we’re brave enough to experiment

- PMLiVE

Pfizer and Triana enter molecular glue degrader partnership worth over $1.5bn

The companies will aim to discover new drugs for cancer and other severe diseases

- PMLiVE

AstraZeneca’s Voydeya recommended by NICE to treat rare blood disorder PNH

The drug has been recommended for use alongside the company’s C5 inhibitors

- PMLiVE

ESMO 2024 – how pharma is breathing life into cancer comms

Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of...

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links